肝血管参与腺氨酸脱氨酶2缺乏症 (DADA2):病例报告和文献综述
Mihaela Sparchez1,2, Laura Damian3, Mihai Adrian Socaciu4
1Second Pediatric Discipline, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400177 Cluj-Napoca, Romania.
氨酸脱氨酶2 (DADA2) 缺乏会导致类似于FNH型结节的肝病变. 在患有DADA2.2的患者中,Etanercept治疗有效地减少了这些肝病变.
科学领域:
- 罕见的遗传疾病 罕见的遗传疾病
- 血管病理学 血管病理学
- 免疫学 免疫学 免疫学
背景情况:
- 氨酸脱氨酶2 (DADA2) 缺乏症是一种罕见的单一性血管病变.
- 在DADA2中肝血管的参与被低估了.
- 神经和血液学特征得到了充分的记录.
研究的目的:
- 在DADA2.2中描述肝血管参与.
- 在Etanercept治疗期间说明病变的演变.
- 综合DADA2肝脏表现的证据.
主要方法:
- 一个女孩患有早期DADA2.2的病例报告.
- 利用对比增强超声波 (CEUS) 和MRI进行肝脏成像.
- 基因测试证实了ADA2突变.
- 在Etanercept治疗期间的长期随访.
主要成果:
- 患者出现了多个类似FNH的肝结节.
- 在9年时间里,etanercept导致了临床稳定和病变回归.
- 姐妹的类似突变显示出更温和的表型,没有肝脏参与.
结论:
- 在DADA2.2中发现了具有FNH外观的大型再生结节的新发现.
- 乙南塞普特证明了有利的肝脏反应与病变减少.
- 案例促进了对DADA2肝病和治疗影响的理解.
更多相关视频
04:33Spinal Hernia Repair and Cauda Equina Repositioning After Lumbar Decompression under Three-Dimensional Microscopy: A Case Report and Literature Review
Published on: November 8, 2024
04:17Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
相关概念视频
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Seedless Vascular Plants
Data Reporting and Recording
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
